NeuroSense Granted Brazilian Patent for PrimeC with Protection Through 2042

On April 6, 2026, NeuroSense Therapeutics Ltd. announced that the Brazilian Patent and Trademark Office (INPI) has granted Brazilian Patent No. BR 112024007727-6 for its lead drug candidate, PrimeC. The patent, titled 'Compositions Comprising Ciprofloxacin and Celecoxib,' provides composition-of-matter protection in Brazil through October 2042. This grant follows similar patent approvals in the United States and Australia, further strengthening the company's global intellectual property portfolio. PrimeC is a proprietary fixed-dose oral therapy combining ciprofloxacin and celecoxib in an extended-release formulation designed to treat amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The company is currently preparing to initiate PARAGON, a Phase 3 pivotal clinical trial for PrimeC in ALS, following positive results from its Phase 2b PARADIGM study and clearance from the FDA. The patent protection supports the long-term development and potential commercialization of PrimeC across multiple neurodegenerative indications.